M&A

News

Gilead strikes again, penning $5bn deal to buy Tubulis

Gilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront.

News

AI giant Anthropic buys Coefficient Bio for $400m

Anthropic has continued its push into the healthcare sector by acquiring New York start-up Coefficient Bio.

News

Neurocrine pays $2.9bn for Soleno and extreme hunger drug

Neurocrine Biosciences has agreed a $2.9bn deal to buy Soleno Therapeutics and its treatment for a rare, genetic form of severe obesity.

News

Alzheimer's biotech Korsana to go public via reverse merger

By merging with Cyclerion, Korsana will get a Nasdaq listing and additional cash to develop its new-generation amyloid-targeting drug for Alzheimer's.

News

Biogen swoops on Apellis with $5.6bn offer

In today's second sizeable M&A deal, Biogen has agreed to buy Apellis for around $5.6 billion, building on its aspirations in nephrology.

News

Eli Lilly makes $7.8bn takeover play for Centessa

Sleep disorder specialist Centessa is heading for an acquisition by Eli Lilly, which has offered $6.3bn for the US and UK-based biotech.

Gilead strikes again, penning $5bn deal to buy Tubulis

AI giant Anthropic buys Coefficient Bio for $400m

Neurocrine pays $2.9bn for Soleno and extreme hunger drug

Alzheimer's biotech Korsana to go public via reverse merger

Biogen swoops on Apellis with $5.6bn offer

Eli Lilly makes $7.8bn takeover play for Centessa

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

M&A

Editor's Picks